Table 1. Long-acting interferon trials... | American Society of Hematology

Table 1.

Long-acting interferon trials

Study	Phase	Comparison	Patients	Follow-up duration	Hematologic CR	Molecular response
PVN1	2	peginterferon alfa-2a	37 with PV	31.4 mo	94.6%	18.9% undetected 72.4% with >50% reduction
MDACC	2	peginterferon alfa-2a	40 with PV 39 with ET	20 mo	70% (PV) 76% (ET)	14% and 6% undetected (PV vs ET) 54% and 38% with >50% reduction (PV vs ET)
PV-PROUD/CONTINUATION-PV	3	Ropeginterferon vs HU	257 with PV	45.5 mo	IFN vs HU 71% vs 51% at 36 months	44% vs 51% at 12 mo (IFN vs HU) 66% vs 27% at 36 mo (IFN vs HU)

Study	Phase	Comparison	Patients	Follow-up duration	Hematologic CR	Molecular response
PVN1	2	peginterferon alfa-2a	37 with PV	31.4 mo	94.6%	18.9% undetected 72.4% with >50% reduction
MDACC	2	peginterferon alfa-2a	40 with PV 39 with ET	20 mo	70% (PV) 76% (ET)	14% and 6% undetected (PV vs ET) 54% and 38% with >50% reduction (PV vs ET)
PV-PROUD/CONTINUATION-PV	3	Ropeginterferon vs HU	257 with PV	45.5 mo	IFN vs HU 71% vs 51% at 36 months	44% vs 51% at 12 mo (IFN vs HU) 66% vs 27% at 36 mo (IFN vs HU)